PE20260287A1 - Compuestos moduladores de receptores de dopamina d3/d2 - Google Patents
Compuestos moduladores de receptores de dopamina d3/d2Info
- Publication number
- PE20260287A1 PE20260287A1 PE2025001450A PE2025001450A PE20260287A1 PE 20260287 A1 PE20260287 A1 PE 20260287A1 PE 2025001450 A PE2025001450 A PE 2025001450A PE 2025001450 A PE2025001450 A PE 2025001450A PE 20260287 A1 PE20260287 A1 PE 20260287A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- dopamine
- piperazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363479530P | 2023-01-11 | 2023-01-11 | |
| PCT/IB2024/000026 WO2024150068A2 (en) | 2023-01-11 | 2024-01-10 | Dopamine d3/d2 receptor modulating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20260287A1 true PE20260287A1 (es) | 2026-02-10 |
Family
ID=89573273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2025001450A PE20260287A1 (es) | 2023-01-11 | 2024-01-10 | Compuestos moduladores de receptores de dopamina d3/d2 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12168007B1 (https=) |
| EP (1) | EP4400495A1 (https=) |
| JP (2) | JP7686096B2 (https=) |
| KR (2) | KR102921799B1 (https=) |
| CN (1) | CN120569367A (https=) |
| AR (1) | AR131577A1 (https=) |
| AU (1) | AU2024208533A1 (https=) |
| CL (1) | CL2025002035A1 (https=) |
| CO (1) | CO2025010725A2 (https=) |
| GE (1) | GEAP202516807A (https=) |
| IL (1) | IL321654A (https=) |
| JO (1) | JOP20250164A1 (https=) |
| MX (1) | MX2025008101A (https=) |
| PE (1) | PE20260287A1 (https=) |
| TW (1) | TW202432139A (https=) |
| WO (1) | WO2024150068A2 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227534B1 (en) * | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| EP1870405A1 (en) | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| CA2937222C (en) | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| WO2020156312A1 (zh) | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| MX2022004473A (es) | 2019-10-29 | 2022-05-06 | Shanghai Hansoh Biomedical Co Ltd | Modificador de un derivado de anillo de cuatro miembros, metodo de preparacion y aplicacion del mismo. |
| US12459931B2 (en) * | 2019-11-05 | 2025-11-04 | Shanghai Hansoh Biomedical Co., Ltd. | Benzothiophene derivative regulator, preparation method therefor and use thereof |
-
2024
- 2024-01-08 KR KR1020240002897A patent/KR102921799B1/ko active Active
- 2024-01-09 AR ARP240100045A patent/AR131577A1/es unknown
- 2024-01-10 EP EP24151077.5A patent/EP4400495A1/en active Pending
- 2024-01-10 US US18/409,478 patent/US12168007B1/en active Active
- 2024-01-10 IL IL321654A patent/IL321654A/en unknown
- 2024-01-10 CN CN202480007498.6A patent/CN120569367A/zh active Pending
- 2024-01-10 TW TW113101017A patent/TW202432139A/zh unknown
- 2024-01-10 PE PE2025001450A patent/PE20260287A1/es unknown
- 2024-01-10 WO PCT/IB2024/000026 patent/WO2024150068A2/en not_active Ceased
- 2024-01-10 GE GEAP202516807A patent/GEAP202516807A/en unknown
- 2024-01-10 JP JP2024001696A patent/JP7686096B2/ja active Active
- 2024-01-10 AU AU2024208533A patent/AU2024208533A1/en active Pending
- 2024-10-29 US US18/930,023 patent/US20250049786A1/en active Pending
-
2025
- 2025-05-19 JP JP2025083110A patent/JP2025122072A/ja active Pending
- 2025-07-09 CL CL2025002035A patent/CL2025002035A1/es unknown
- 2025-07-10 JO JOJO/P/2025/0164A patent/JOP20250164A1/ar unknown
- 2025-07-10 MX MX2025008101A patent/MX2025008101A/es unknown
- 2025-08-05 CO CONC2025/0010725A patent/CO2025010725A2/es unknown
-
2026
- 2026-01-29 KR KR1020260017571A patent/KR20260019592A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202432139A (zh) | 2024-08-16 |
| JP7686096B2 (ja) | 2025-05-30 |
| JP2024098972A (ja) | 2024-07-24 |
| EP4400495A1 (en) | 2024-07-17 |
| CN120569367A (zh) | 2025-08-29 |
| JP2025122072A (ja) | 2025-08-20 |
| IL321654A (en) | 2025-08-01 |
| KR20240112213A (ko) | 2024-07-18 |
| AU2024208533A1 (en) | 2025-07-10 |
| JOP20250164A1 (ar) | 2025-07-10 |
| KR102921799B1 (ko) | 2026-02-04 |
| WO2024150068A2 (en) | 2024-07-18 |
| KR20260019592A (ko) | 2026-02-10 |
| AR131577A1 (es) | 2025-04-09 |
| WO2024150068A3 (en) | 2024-08-22 |
| MX2025008101A (es) | 2025-08-01 |
| GEAP202516807A (en) | 2025-08-25 |
| CL2025002035A1 (es) | 2025-10-03 |
| US20250049786A1 (en) | 2025-02-13 |
| CO2025010725A2 (es) | 2025-08-29 |
| US12168007B1 (en) | 2024-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231938A1 (es) | Inhibidores de cdk y metodos de uso de estos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| ME00564A (hr) | Derivati (tio) karbamoil-cikloheksana kao antagonisti d3/d2 receptora | |
| AR115949A1 (es) | Compuestos heterocíclicos | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| PE20221460A1 (es) | Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de cftr deficiente | |
| PE20091033A1 (es) | Derivados de nicotinamida como agentes anticancerosos y su preparacion | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR059249A1 (es) | Compuesto amina trisustituido | |
| PE20040589A1 (es) | Tiazolidinonas y su preparacion como medicamentos | |
| PE20050012A1 (es) | Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2 | |
| AR044036A1 (es) | Compuestos de pirazolopirimidinas y pirazolopiridinas como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos | |
| PE20080076A1 (es) | Derivados de amida como inhibidores de la quinasa c-fms | |
| UY30387A1 (es) | Nuevos compuestos | |
| PE20030100A1 (es) | Compuestos de n-formil-hidroxilamina | |
| AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
| PE20140966A1 (es) | Quinazolincarboxamida azetidinas | |
| AR120029A1 (es) | Compuestos heterocíclicos | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| BR112022013849A2 (pt) | Novo derivado de pirazol | |
| PE20251845A1 (es) | Compuestos novedosos como moduladores de la inhibicion de nlrp3 | |
| CO2023006912A2 (es) | Nuevos derivados de indazol acetileno | |
| PY22111032A (es) | Inhibidores de dhodh que contienen un bioisostero de acido carboxilico | |
| PE20260287A1 (es) | Compuestos moduladores de receptores de dopamina d3/d2 | |
| PE20252682A1 (es) | Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlrp3 para el tratamiento de, por ejemplo, enfermedades inflamatorias |